English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Loans
    HomeNewsWyeth pharmaceuticals

    Wyeth Pharmaceuticals

    Jump to
    • Glenmark up 2% on USFDA nod for oral contraceptive drug

      Glenmark up 2% on USFDA nod for oral contraceptive drug

      Glenmark Generics, a subsidiary of Glenmark Pharmaceuticals, has received a final approval from USFDA for the oral contraceptive Levonorgestrel/Ethinyl Estradiol Tablets.

    • Wyeth's claim on Protonix unjustified: Sun Pharma

      Wyeth's claim on Protonix unjustified: Sun Pharma

      “We strongly believe that we have reasons to disagree with the claim that they have made. Fundamentally, we also believe that the patent invalidated is something that we will continue to fight for, Uday Baldota, vice president - investor relations, Sun Pharma told CNBC-TV18.

    • Wyeth claims USD960m from Sun Pharma in Protonix case

      Wyeth claims USD960m from Sun Pharma in Protonix case

      Wyeth Pharmaceuticals Inc is seeking USD 960 million in damages from Sun Pharmaceutical Industries for alleged patent infringement in launching a generic version of acid reflux drug Protonix in the United States, the Indian company said.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347